128 related articles for article (PubMed ID: 8600343)
1. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.
Neumann Y; Toren A; Rechavi G; Seifried B; Shoham NG; Mandel M; Kenet G; Sharon N; Sadeh M; Navon R
Med Pediatr Oncol; 1996 Apr; 26(4):280-3. PubMed ID: 8600343
[TBL] [Abstract][Full Text] [Related]
2. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.
Schiavetti A; Frascarelli M; Uccini S; Novelli A
Pediatr Blood Cancer; 2004 Oct; 43(5):606-9. PubMed ID: 15382281
[TBL] [Abstract][Full Text] [Related]
3. Vincristine neurotoxicity in the presence of hereditary neuropathy.
Trobaugh-Lotrario AD; Smith AA; Odom LF
Med Pediatr Oncol; 2003 Jan; 40(1):39-43. PubMed ID: 12426685
[No Abstract] [Full Text] [Related]
4. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Brach del Prever A; Iantorno D; Forni C; Campanacci M
Minerva Pediatr; 1995 Nov; 47(11):457-69. PubMed ID: 8684341
[TBL] [Abstract][Full Text] [Related]
6. [Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].
Uno S; Katayama K; Dobashi N; Hirano A; Ogihara A; Yamazaki H; Usui N; Kobayashi T; Inoue K; Kuraishi Y
Rinsho Ketsueki; 1999 May; 40(5):414-9. PubMed ID: 10390891
[TBL] [Abstract][Full Text] [Related]
7. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis.
Olek MJ; Bordeaux B; Leshner RT
J Am Osteopath Assoc; 1999 Mar; 99(3):165-7. PubMed ID: 10217912
[TBL] [Abstract][Full Text] [Related]
8. Charcot-Marie-Tooth disease and vincristine.
Orejana-García AM; Pascual-Huerta J; Pérez-Melero A
J Am Podiatr Med Assoc; 2003; 93(3):229-33. PubMed ID: 12756314
[TBL] [Abstract][Full Text] [Related]
9. Neurophysiology and molecular genetics of Charcot-Marie-Tooth type 1 neuropathy in Croatian children: follow-up study.
Barisić N; Mihatov I
Croat Med J; 2000 Sep; 41(3):306-13. PubMed ID: 10962051
[TBL] [Abstract][Full Text] [Related]
10. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.
Mercuri E; Poulton J; Buck J; Broadbent V; Bamford M; Jungbluth H; Manzur AY; Muntoni F
Arch Dis Child; 1999 Nov; 81(5):442-3. PubMed ID: 10519723
[TBL] [Abstract][Full Text] [Related]
11. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
Hildebrandt G; Holler E; Woenkhaus M; Quarch G; Reichle A; Schalke B; Andreesen R
Ann Oncol; 2000 Jun; 11(6):743-7. PubMed ID: 10942065
[TBL] [Abstract][Full Text] [Related]
12. Congenital pes cavus in a Charcot-Marie-tooth disease type 1A newborn.
Fusco C; Frattini D; Scarano A; Giustina ED
Pediatr Neurol; 2009 Jun; 40(6):461-4. PubMed ID: 19433282
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the cavus foot. Deformity in the pediatric patient with Charcot-Marie-Tooth.
Olney B
Foot Ankle Clin; 2000 Jun; 5(2):305-15. PubMed ID: 11232232
[TBL] [Abstract][Full Text] [Related]
14. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease.
Weimer LH; Podwall D
J Neurol Sci; 2006 Mar; 242(1-2):47-54. PubMed ID: 16386273
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of hereditary neuropathies.
Chance PF
J Child Neurol; 1999 Jan; 14(1):43-52. PubMed ID: 10223854
[No Abstract] [Full Text] [Related]
16. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy).
Cil T; Altintas A; Tamam Y; Battaloğlu E; Isikdogan A
J Pediatr Hematol Oncol; 2009 Oct; 31(10):787-9. PubMed ID: 19770686
[TBL] [Abstract][Full Text] [Related]
17. [A case of Charcot-Marie-Tooth disease 1 B with Val 146Phe mutation of myelin protein zero showing a severe clinical phenotype].
Ohnishi A; Aoki A; Yamamoto T; Tsuji S
Rinsho Shinkeigaku; 2000 Mar; 40(3):268-70. PubMed ID: 10885340
[TBL] [Abstract][Full Text] [Related]
18. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.
Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T
J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic variability in autosomal recessive axonal Charcot-Marie-Tooth disease due to the R298C mutation in lamin A/C.
Tazir M; Azzedine H; Assami S; Sindou P; Nouioua S; Zemmouri R; Hamadouche T; Chaouch M; Feingold J; Vallat JM; Leguern E; Grid D
Brain; 2004 Jan; 127(Pt 1):154-63. PubMed ID: 14607793
[TBL] [Abstract][Full Text] [Related]
20. Patients homozygous for the 17p11.2 duplication in Charcot-Marie-Tooth type 1A disease.
LeGuern E; Gouider R; Mabin D; Tardieu S; Birouk N; Parent P; Bouche P; Brice A
Ann Neurol; 1997 Jan; 41(1):104-8. PubMed ID: 9005872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
